Pro-family tax policy: The case of the Tax Cuts and Jobs Act
There is currently a debate among policy analysts and commentators about whether the Tax Cuts and Jobs Act of 2017 (TCJA) was “pro-family.”
Hey World: Do Not Ban E-Cigarettes
There is a hot debate in many countries over youth use of e-cigarettes, electronic devices that deliver nicotine to consumers without the deadly tar found in the smoke from traditional cigarettes. Although nicotine is not a carcinogen, it is still bad for developing brains and should not be used by young adults or pregnant women. At the same time, e-cigarettes offer real advantages over traditional tobacco products for smokers who are otherwise unable to quit.
The Economics of Biologic Drugs
The market for biologic drugs in the United States is large and growing. Total US biologic sales in 2018 is estimated to have been $125 billion, an increase of 50 percent since 2014.
Biologics are Not Natural Monopolies
Recently, several physicians and health policy analysts took to the Health Affairs blog to propose what was, to anyone who has been following biosimilars for the last decade or more, a surprising and concerning idea: that biosimilars should be abandoned.
2018 Charitable Giving Dips, as Predicted
A Giving USA report released last week shows that US households’ charitable donations in 2018 experienced the largest decline since the Great Recession. We hate to say we told you so, but we told you so.
Action on Climate Change Should Not Include Creation of New Entitlements
Over the last two years, the United States has scaled back Obama-era climate change policies, withdrawing from the Paris Agreement and rolling back climate-related regulations.
- FDA Continues to Expedite Biosimilar Development
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
- How Pharmaceutical Tariffs Will Affect US Health Care Costs
- MGA Releases New Report Quantifying the Economic Impact of Healthcare Distributors
- The Unsung Hero of the OBBBA: Permanent Expensing
- Alex Brill Interviewed by Biosimilars Review & Report
- MGA Releases New White Paper on Medicare Price Negotiations and Drug Competition
